Exscientia Links With Scripp Research’s Calibr To Apply AI To COVID-19
UK Diamond Light Source And Oxford University Part Of Initiative
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.
You may also be interested in...
Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.